Jumei Shi
YOU?
Author Swipe
View article: Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis Open
Background Enolase 1 (ENO1) is a conserved glycolytic enzyme that regulates glycolysis metabolism. However, its role beyond glycolysis in the pathophysiology of multiple myeloma (MM) remains largely elusive. Herein, this study aimed to elu…
View article: Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay
Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay Open
The study identified novel molecules as TRIP13 inhibitors with good anti-multiple myeloma activity, which could be developed into TRIP13-based multi-target drugs.
View article: Exploration of the mechanism of Lithospermum erythrorhizon oil in treating atopic dermatitis based on network pharmacology and experimental validation of the PI3K-Akt pathway regulation
Exploration of the mechanism of Lithospermum erythrorhizon oil in treating atopic dermatitis based on network pharmacology and experimental validation of the PI3K-Akt pathway regulation Open
Lithospermum erythrorhizon oil exerts multi-target, multi-pathway therapeutic effects in AD, potentially through suppressing Th2-mediated immune responses and the PI3K-Akt signaling pathway, suggesting novel avenues for AD treatment strate…
View article: Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease Open
This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. …
View article: Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport
Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport Open
Chemoresistance is an important factor in multiple myeloma (MM) relapse and overall survival. However, the mechanism underlying resistance remains unclear. In this study, we identified adenine nucleotide translocase 3 (ANT3) as a novel bio…
View article: Validation and development of a scoring system for comprehensively evaluating arterial damage in the elderly chinese
Validation and development of a scoring system for comprehensively evaluating arterial damage in the elderly chinese Open
Background and aims Existing assessments on arterial damage focus on specific segments of arterial system (e.g., carotid artery), lacking a comprehensive index to evaluate overall arterial health. We aimed to integrate existing assessments…
View article: EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma
EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma Open
Epigenetic modifications play an important role in cellular senescence, and enhancer of zeste homolog 2 (EZH2) is a key methyltransferase involved in epigenetic remodeling in multiple myeloma (MM) cells. We have previously demonstrated tha…
View article: <scp>TI17</scp>, a novel compound, exerts <scp>anti‐MM</scp> activity by impairing Trip13 function of <scp>DSBs</scp> repair and enhancing <scp>DNA</scp> damage
<span>TI17</span>, a novel compound, exerts <span>anti‐MM</span> activity by impairing Trip13 function of <span>DSBs</span> repair and enhancing <span>DNA</span> damage Open
Background Thyroid hormone receptor interacting protein 13 (Trip13) is an AAA‐ATPase that regulates the assembly or disassembly protein complexes and mediates Double‐strand breaks (DSBs) repair. Overexpression of Trip13 has been detected i…
View article: Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation Open
Multiple myeloma (MM) is characterized by excessive aggregation of B-cell-derived malignant plasma cells in the hematopoietic system of bone marrow. Previously, we synthesized an innovative molecule named dihydrocelastrol (DHCE) from celas…
View article: Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma Open
Multiple myeloma (MM) remains incurable due to drug resistance. Ribosomal protein S3 (RPS3) has been identified as a non-Rel subunit of NF-κB. However, the detailed biological roles of RPS3 remain unclear. Here, we report for the first tim…
View article: Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Open
Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
View article: Figure S1-S6, Table S1-S2 from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression
Figure S1-S6, Table S1-S2 from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression Open
Supplementary Data descripted that DCZ0415 suppresses multiple myeloma progression via targeting TRIP13
View article: Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Open
Supplementary Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
View article: Data from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression
Data from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression Open
The AAA-ATPase TRIP13 drives multiple myeloma progression. Here, we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small-molecule inhibitor targeting TRIP13 was identified on the basis of the crystal st…
View article: Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Open
Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset…
View article: Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Data from Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Open
Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset…
View article: Data from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression
Data from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression Open
The AAA-ATPase TRIP13 drives multiple myeloma progression. Here, we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small-molecule inhibitor targeting TRIP13 was identified on the basis of the crystal st…
View article: Figure S1-S6, Table S1-S2 from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression
Figure S1-S6, Table S1-S2 from A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression Open
Supplementary Data descripted that DCZ0415 suppresses multiple myeloma progression via targeting TRIP13
View article: Data from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Data from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation Open
Iron homeostasis is disrupted in multiple myeloma, a difficult-to-cure plasma cell malignancy with lytic bone lesions. Here, we systematically analyzed iron gene expression signature and demonstrated that mRNA expression of iron exporter f…
View article: Data from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Data from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation Open
Iron homeostasis is disrupted in multiple myeloma, a difficult-to-cure plasma cell malignancy with lytic bone lesions. Here, we systematically analyzed iron gene expression signature and demonstrated that mRNA expression of iron exporter f…
View article: Supplementary Figures S1-3, Tables S1-2 from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Supplementary Figures S1-3, Tables S1-2 from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation Open
Supplementary Figures S1-3, Tables S1-2. Figure S.1. FPN1 downregulates STAT3-MCL-1 signaling, related to Figure 2 and 4. Figure S.2. FPN1 is downregulated in the initial phase of osteoclastogenesis, related to Figure 5. Figure S.3. High F…
View article: Supplementary Figures S1-3, Tables S1-2 from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation
Supplementary Figures S1-3, Tables S1-2 from Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation Open
Supplementary Figures S1-3, Tables S1-2. Figure S.1. FPN1 downregulates STAT3-MCL-1 signaling, related to Figure 2 and 4. Figure S.2. FPN1 is downregulated in the initial phase of osteoclastogenesis, related to Figure 5. Figure S.3. High F…
View article: A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway Open
Multiple myeloma (MM), the second most common haematological malignancy, is currently incurable because patients often develop multiple drug resistance and experience subsequent relapse of the disease. This study aims to identify a potenti…
View article: Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma Open
Background Aberrant DNA repair pathways contribute to malignant transformation or disease progression and the acquisition of drug resistance in multiple myeloma (MM); therefore, these pathways could be therapeutically exploited. Ribonucleo…